Abiopharma

BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025

Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting

(30% Negative) UNIVERSAL HEALTH SERVICES, INC. (UHS) Reports Q4 2025 Financial Results

Josh Ruben Joins PetVivo Holdings, Inc. Board of Directors

Revvity to Present at Upcoming Investor Conferences

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

Cybin Announces $175 Million Registered Direct Offering

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

Cidara Therapeutics to Participate in November Investor Conferences

Soleno Therapeutics to Participate in Upcoming November Conferences

New Form 6-K - GSK plc Filed: 2025-10-28 AccNo: 0001654954-25-012261 Size: 1 MB

(85% Positive) Edesa Biotech, Inc. (EDSA) Announces Clinical Development Update